Agenus Inc insider trading
Every open-market purchase and sale by Agenus Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Does following Agenus Inc’s insiders pay?
From March 11, 2010 to February 15, 2024, 15 insiders reported 12 open-market purchases and 20 sales not made under a pre-set plan in Agenus Inc. Twelve months after each purchase was reported, the shares were −51.7% against the S&P 500 on average (median −51.7%), over 1 purchase with a full year of prices; 0% beat the index. After sales, the shares moved −41.8% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on September 9, 2016 into $8,640 by November 2, 2026, −1.4% a year. It held shares 10% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $15,265 (+4.3% a year), and held throughout $41,743 (+15.2%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Armen Garo H | See Remarks | 7 | — | — | 3 | −41.5% (1) | February 15, 2024 |
| Incyte Corp | 10% owner | 1 | — | — | 2 | — | June 18, 2020 |
| Klaskin Christine M | PFO & PAO | 0 | — | — | 3 | −41.5% (1) | September 14, 2021 |
| Valentine Karen | Chief Legal Officer | 0 | — | — | 3 | — | December 14, 2017 |
| Wentworth Kerry | VP, Clinical, Reg, & Quality | 0 | — | — | 2 | — | December 29, 2011 |
| Wiinberg Ulf | Director | 2 | −51.7% (1) | 0% | 0 | — | November 17, 2023 |
| Ballantyne Charles Evan | Chief Financial Officer | 1 | — | — | 0 | — | September 29, 2015 |
| Baysal Ozer | Chief Commercial Officer | 0 | — | — | 1 | — | December 14, 2017 |
| Buell Jennifer | Chief Communications Officer | 0 | — | — | 1 | — | December 14, 2017 |
| Duncan Alex | Chief Technology Officer | 0 | — | — | 1 | — | December 14, 2017 |
| Malik Shahzad | Director | 0 | — | — | 1 | −46.9% (1) | April 30, 2015 |
| O'day Steven J | Chief Medical Officer | 0 | — | — | 1 | — | January 6, 2022 |
| Qvt Fund V LP | 10% owner | 0 | — | — | 1 | −37.2% (1) | January 13, 2015 |
| Sharp Shalini | CFO | 0 | — | — | 1 | — | December 23, 2011 |
| Wright Timothy | Director | 1 | — | — | 0 | — | May 19, 2010 |